chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Brachial Neuritis, lower branch lesion developing about 60 days post immunization accompanied by extreme unrelenting pain in upper right back and shoulder area, extreme weakness in third and fourth fingers, arm pain, loss of ulnar and triceps reflex, wasting of muscles, scapula winging.  Onset was gradual at first.  On 10 /13 had reaction left arm hot and sore hurting to touch or move or lay on, reported to MD.
01/13/23 presents to ED for "abdominal pain". PMHx of "anxiety, GERD, hypothyroidism, HLD, and a fib"
Started to experience dizziness and vision blurriness 5 days after first does. (couldn?t even read street signs!) night vision is now horrible! Headaches
No adverse effect reported; received improperly stored VARIVAX; This spontaneous report was received from an office manager, concerning a 4 year old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant medications were not reported.   On 05-AUG-2019, the patient was vaccinated with improperly stored varicella virus vaccine live (oka/merck)(VARIVAX), lot # S008692 and expiration date on 21-MAR-2021, for prophylaxis. The vaccine was reconstituted with properly stored sterile diluent. No adverse effect was reported. No product quality complalint was involved.   This is one of two reports received from the same reporter.; Sender's Comments:  US-009507513-1908USA002281:
warm touch around the site of injection; Itchy around the site of injection; Knot around the site of injection; Red around the site of injection; Sore around the site of injection; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (warm touch around the site of injection), VACCINATION SITE PRURITUS (Itchy around the site of injection), VACCINATION SITE INDURATION (Knot around the site of injection), VACCINATION SITE ERYTHEMA (Red around the site of injection) and VACCINATION SITE PAIN (Sore around the site of injection) in an 82-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Jan-2021, the patient experienced VACCINATION SITE WARMTH (warm touch around the site of injection), VACCINATION SITE PRURITUS (Itchy around the site of injection), VACCINATION SITE INDURATION (Knot around the site of injection), VACCINATION SITE ERYTHEMA (Red around the site of injection) and VACCINATION SITE PAIN (Sore around the site of injection). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL A) at an unspecified dose and frequency. At the time of the report, VACCINATION SITE WARMTH (warm touch around the site of injection), VACCINATION SITE PRURITUS (Itchy around the site of injection), VACCINATION SITE INDURATION (Knot around the site of injection), VACCINATION SITE ERYTHEMA (Red around the site of injection) and VACCINATION SITE PAIN (Sore around the site of injection) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
This case was reported by a pharmacist via call center representative and described the occurrence of skin eruption in a 17-year-old female patient who received MENVEO (batch number M15023, expiry date 31st May 2016). On 16th February 2016, the patient received MENVEO. On 16th February 2016, less than a day after receiving MENVEO, the patient experienced skin eruption, adverse reaction and inappropriate preparation of medication. On an unknown date, the outcome of the skin eruption, adverse reaction and inappropriate preparation of medication were unknown. It was unknown if the reporter considered the skin eruption and adverse reaction to be related to MENVEO. Additional details were received as follows: The patient inadvertently received only the liquid meningococcal CYW-135 portion of the MENVEO, which led to an inappropriate preparation of the medication. The patient experienced breaking out and a reaction, which could not be clarified.
24 hours very sore/tender arm (felt like getting a typhoid shot) December 29, difficulty sleeping, restlessness, extreme, Fatigue all week, woke up 4 days later (January 1, 2021) with raised  painful sore bumps on right side of palate,. Day two crossed midline of palate, Day three entire roof of mouth, and tip of tongue. Painful to drink, eat, and brush teeth.
dizziness.; This non-serious case was reported by a consumer via call center representative and described the occurrence of dizziness in a 91-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On 27-OCT-2023, the patient received Arexvy. On 07-NOV-2023, 11 days after receiving Arexvy, the patient experienced dizziness (Verbatim: dizziness.). The outcome of the dizziness was not resolved.   It was unknown if the reporter considered the dizziness to be related to Arexvy.     It was unknown if the company considered the dizziness to be related to Arexvy.   Additional Information: GSK receipt date: 08-NOV-2023 The patient reported that she received a dose of Arexvy and day before reporting and on day of reporting she had been experiencing dizziness. The reporter did not consent to follow up.
Information has been received from a pharmacist concerning an adult female who was recently vaccinated with a dose of measles virus vaccine live (Moraten) (+) mumps virus vaccine live (Jeryl Lynn) (+) rubella virus vaccine live (Wistar RA 27/3). Subsequently, the pt developed joint pain and a low grade fever. Unspecified medical attention was sought. The pt was treated with acetaminophen (Tylenol).  The pharmacist reported that another pt developed joint pain and low grade fever post vaccination with measles virus vaccine live (Moraten) (+) mumps virus vaccine live (Jeryl Lynn) (+) rubella virus vaccine live (Wistar RA 27/3). Additional information has been requested.
lymph nodes in her armpit were enlarged, in the same side of the injection; Lymph node pain; lymph nodes in the neck were swollen, in the same side of the injection.; This spontaneous case was reported by a health care professional and describes the occurrence of VACCINATION SITE LYMPHADENOPATHY (lymph nodes in her armpit were enlarged, in the same side of the injection), LYMPH NODE PAIN (Lymph node pain) and LYMPHADENOPATHY (lymph nodes in the neck were swollen, in the same side of the injection.) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Jan-2021, the patient experienced VACCINATION SITE LYMPHADENOPATHY (lymph nodes in her armpit were enlarged, in the same side of the injection), LYMPH NODE PAIN (Lymph node pain) and LYMPHADENOPATHY (lymph nodes in the neck were swollen, in the same side of the injection.). On 22-Jan-2021, VACCINATION SITE LYMPHADENOPATHY (lymph nodes in her armpit were enlarged, in the same side of the injection), LYMPH NODE PAIN (Lymph node pain) and LYMPHADENOPATHY (lymph nodes in the neck were swollen, in the same side of the injection.) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitants were reported. No treatment was reported.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. Further information has been requested.
States "After I got the Tdap vaccine my arm hurt and then my neck started hurting.  My arm is not sore anymore but my neck is still in pain, I can't turn my head without pain so I have to turn my entire body. I haven't done anything out of the ordinary so I was wondering if this could be from the Tdap vaccine."
Chills; fever; Severe headache; This spontaneous case was reported by a patient and describes the occurrence of CHILLS (Chills), PYREXIA (fever) and HEADACHE (Severe headache) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     The patient's past medical history included No adverse event (no historical conditions reported).    On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced CHILLS (Chills), PYREXIA (fever) and HEADACHE (Severe headache). At the time of the report, CHILLS (Chills), PYREXIA (fever) and HEADACHE (Severe headache) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Limited information regarding the events has been provided at this time and a causal relationship cannot be excluded; Sender's Comments: Limited information regarding the events has been provided at this time and a causal relationship cannot be excluded
This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of SKIN REACTION (six to eight red bumps appeared on her thumbs whose center was tender to the touch on both) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028L20A) for COVID-19 vaccination.     Concurrent medical conditions included High cholesterol (Cholesterol levels now fine), Penicillin allergy and Allergy to antibiotic (Bactrim). Concomitant products included ACETYLSALICYLIC ACID (BABY ASPIRIN) for Aneurysm, EZETIMIBE (ZETIA) for High cholesterol, FISH OIL (OMEGA 3 FISH OIL [FISH OIL]) for Macular degeneration.    On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Feb-2021, the patient experienced SKIN REACTION (six to eight red bumps appeared on her thumbs whose center was tender to the touch on both). At the time of the report, SKIN REACTION (six to eight red bumps appeared on her thumbs whose center was tender to the touch on both) had resolved with sequelae.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       patient states that some bumps were swollen, tender, sore for both the hands. concomitant medication include supplemental iron 65 mg 3times a week for low stores of iron AREDS 2 with multivitamins 2 daily for macular issues. treatment medication include steroid cream,listerine No lab test were done. second dose was administered on 25-feb-2021 right arm   Most recent FOLLOW-UP information incorporated above includes: On 28-Apr-2021: Added treatment medication.Updated patient demographics, relevant history, Concomitant medication and outcome of the events.
Ventricular tachycardia started  9/6/2021 at 7 pm exactly 14 days after my J&J shot. I went to ER 9/7/2021 at 11 am. Zero issues prior to this shot. Healthy 53-year-old. No medicines. Due to damage in heart had to undergo epicardial ablation.
Severe pain in upper back, right side.  Pain persisted for the next few days and after a week I had a full blown case of shingles, complete with blisters up and down my right arm.
Dizziness, no loss of consciousness. 1 event was fine within a few minutes. Pt has no underlying disease and currently in good health.
About two weeks after my vaccine I started to experience extreme joint pain in my arms, shoulders, legs, and hips. I went to see my doctor on April 27th, and he drew my blood. I was diagnosed with polymyalgia rheumatica. I was given diclofenac 75mg, prednisone 5mg.
About 6 months after the second dose I started to have bad rash and painful. Diagnosed with auto immune disease called Bullous Pemphigoid. Doctor tried steroid creams, oral steroids, and prednisone that did not work. Also tried niacin, doxycycline, and clobetasol, which I am taking now. Condition has been up and down since diagnosis.
20~30 days after 2nd dose of vaccine, one night I had strong rapid heart beat, the heart ran like a wild horse for 2+ hours with speed and strength up and down like irregular cycling, occasionally the heart seemed to tend jumping out of roof. My whole body felt weak with sweating, and a little dizziness. After a week, it happened one more time. I called Dr.'s office, and Dr. put heart monitor on me for 14 days twice (one in May and one in July). Both caught Supraventricular Tachycardia. But since May, I do not have strong symptoms any more.
This case was reported by a consumer via call center representative and described the occurrence of fatigue in a adult male patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, 7 days after receiving SHINGRIX, the patient experienced fatigue, shivering, memory loss, upset stomach, abnormal vision, headache and fever. On an unknown date, the outcome of the fatigue, shivering, memory loss, upset stomach, abnormal vision, headache and fever were not recovered/not resolved. It was unknown if the reporter considered the fatigue, shivering, memory loss, upset stomach, abnormal vision, headache and fever to be related to SHINGRIX. Additional details were as follows: The age at vaccination was not reported. The patient received SHINGRIX vaccine in the left arm approximately 2 to 3 months before the reporting date. The patient reported that he experienced the symptoms a week after receiving the SHINGRIX vaccine. The vision problem was stated as being an issue when he drives. The patient also said he had a hard time remembering things lately.  The patient had provided contact details of his physician.
Delayed menstruation (1 week) Abnormal Uterine Bleeding (for 19/23 days) Heart Palpitations & increased heart rate (resting & active) Enlarged Thyroid, Cystic Nodule
Bright red, painful area at injection site upper arm (had received Pneumovax 10 years prior).
Patient reported having sore left arm and cramping which started within 24 hours.  Then it spread to both feet with pain and crampin.  Also experienced chest pain, tightness and shortness of breath.  Patient did report having rheumatoid arthritis and some other autoimmune issues as well as neuropathy.
Received expired dose past manufacturer expiration date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received expired dose past manufacturer expiration date) in an 82-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 048C21A and 013A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 10-Nov-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 10-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received expired dose past manufacturer expiration date). On 10-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Received expired dose past manufacturer expiration date) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported.   Most recent FOLLOW-UP information incorporated above includes: On 10-Nov-2021: Follow-up received: Patient demographic and dose details were updated.
Pneumonia NOS; something was swollen; Cough; feeling very bad right now; shivering; fever; This spontaneous case was reported by a consumer and describes the occurrence of PNEUMONIA (Pneumonia NOS) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PNEUMONIA (Pneumonia NOS) (seriousness criterion medically significant), SWELLING (something was swollen), CHILLS (shivering), COUGH (Cough), PYREXIA (fever) and MALAISE (feeling very bad right now). At the time of the report, PNEUMONIA (Pneumonia NOS), SWELLING (something was swollen), CHILLS (shivering), COUGH (Cough), PYREXIA (fever) and MALAISE (feeling very bad right now) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.  Treatment information was not provided.  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. Events Pneumonia NOS and Cough were added as per narrative.   This case was linked to MOD-2021-244433 (Patient Link).; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. Events Pneumonia NOS and Cough were added as per narrative.
Information regarding Flumist (2003-2004 formula)(influenza virus vaccine, live intranasal (2003-2004 formula) nasal solution (frozen)) was received from a healthcare professional regarding a 6 year old female pt who experienced nasal congestion, headache and fever.  One week prior to the administration of Flumist, the pt developed wheezing.  Treatment consisted of an unspecified dose of oral steroids.  On 12/08/03, at 6 years of age, the pt received the first dose of Flumist (2003-2004 formula).  Indication for flumist (2003-2004 formula) was immunization.  Dose regimen was 1 dose 1 time per day (IN).  The pt was not taking concomitant therapy.  No other vaccines were administered.  On 12/09/03, the pt experienced a headache.  On 12/10/03, the headache persisted and the pt developed nasal congestion and fever ranging from 102 deg F to 103 deg F.  As of the date of this report, the event has not been resolved.  No additional information was available at the time of this report.
On March 25, 2021 at 6:35pm I went into the urgent care center with the signs and symptoms of a sinus infection. The center issued me a rapid COVID test and I came back with a positive test result. By 9:00pm on March 25th, I lost my ability to taste and smell. I have a very bad chest cough and am having a stuffed up nose.
Arm started to turn red, size of a dollar; This spontaneous case was reported by a health care professional and describes the occurrence of ERYTHEMA (Arm started to turn red, size of a dollar) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event, Hypertension and Cholesterol.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Jan-2021, the patient experienced ERYTHEMA (Arm started to turn red, size of a dollar). On 29-Jan-2021, ERYTHEMA (Arm started to turn red, size of a dollar) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   Based on the current available information which shows a temporal association between the use of mRNA-1273 and the onset of the events, a causal relationship cannot be excluded.   Reporter did not allow further contact; Sender's Comments: Based on the current available information which shows a temporal association between the use of mRNA-1273 and the onset of the events, a causal relationship cannot be excluded.
pt recv vax 9OCT96 & 28OCT96 pt exp pneumococcal septicemia & a lt lower lobe pneumonia;pt hosp;
patient was asked to stay in the waiting are for 15 minutes.he went and sat down then he got up to talk to his wife at that time he felt sick and passed out. his breathing was shallow and he was unresponsive for 2 minutes. he was pale. paramedics were called and they came right away and assessed him. he did not need any medical help. he felt fine. they did not take him to hospital.
Onset of discomfort in mid-back (R) side. The next day he noted lesions on his back that were still achy. Symptoms: Rash, other nonspecific skin eruption, Disturbance of skin sensation.
COVID 19 Treatment; COVID 19 Treatment; interchange of vaccine products; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 78-year-old female patient (not pregnant) received bnt162b2, bnt162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 27Sep2023 as dose number unknown, single (Batch/Lot number: unknown) at the age of 78 years for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 21May2022 as dose number unknown, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "type 2 diabetes" (unspecified if ongoing); "hypertension" (unspecified if ongoing); "restless legs" (unspecified if ongoing); "high cholesterol" (unspecified if ongoing); "known allergies: some shell fish" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Amoxcillin, reaction(s): "known allergies: amoxcillin"; Aurithromycin, reaction(s): "known allergies: aurithromycin"; Zithromax, reaction(s): "known allergies: zithromax". The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 27Sep2023, outcome "recovered"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Oct2023, outcome "recovered" (14Oct2023) and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (14Oct2023) Negative. Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: Patient took Paxlovid from 05Oct2023 to 10Oct2023.   The information on the batch/lot number for bnt162b2, bnt162b2 omi ba.4-5 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300330381 same patient, different drug/event;US-PFIZER INC-202300330416 same patient, different vaccine dose/event;
Low grade fever, generalized rash 1/26/16 some hives/some papules (started with facial rash approximately 1/25/16). Patient presents with skin rash x2 days. Fever slight, low grade up to 100. Nasal congestion started yesterday. Temperature 98.6 degrees F (37 degrees C), temperature source Temporal Artery, weight 20 lb 12 oz (9.412 kg). Low fever started Tuesday, last pm again low. Some congestion x 1 days. No cough. Eats fair. Had photo from yesterday and rash was more intense, cheeks bright red (was in the bath). Seemed tender to touch earlier. Rash (slightly raised hive-like rash on upper thighs, sides and back, calves with similar rash but also some more raised red papules. Back of upper arms with faint hive like rash also noted.
The mother of a 3 month old male reported that her son received his 2nd dose of Prevnar in 9/00 (approx. 3 months of age when received 2nd dose). The pt recently recovered from a "chronic dermatitis around his mouth" that resolved when he was switched to a latex-free bottle. In 11/00, the pt (approx. 5 months of age) developed a bilateral ear infection and sinusitis and was prescribed Zithromax (azithromycin). In 12/00, the symptoms were not resolving and the pt was prescribed Cefzil (cefprozil). NOTE: See report HQ8556919MAR2001 for events following the 3rd dose of Prevnar.
no fever p/DTP; devel a mixed-type seizure disorder; 1-2 wks p/2nd DTP; tx w/Phenobarbitol, Clorazepam;